Intellectual properties and intangible assets are often the foundation of a Company's value and growth. But, Biotech companies, especially start-ups, may have little else other than their IP. This creates a high level of importance on the management, strategic development and valuation of those assets. As a result, proper management and credible valuations affect business strategy, competitive responses, subsequent capital acquisition, and even business survival. The valuation of intellectual property often involves many parties assessing the same assets from many different points of view. In addition, a Company's IP also creates value in many ways-licenses, new product development, competitive advantage, and royalties are just the beginning.
Our panel includes Tom Stephenson, Co-founder of the Verge Fund, Ed Street, CPA/APV/CFF, CVA with REDW, and Loraine Upham, President and CEO of Azano Pharmaceuticals.
The panel will provide insight and real life examples into the importance proper management of IP, how IP is valued including a view of the many conflicting priorities and expectations in valuing IP, and discuss the best practices in monetizing and valuing the many potential income streams your IP could create.
Non-members register by credit card here:Members please sign up here:
NMBio NonMember rate, (includes lunch) $35
Cost free to current NMBio members
Date: Tuesday, June 12 2012
Time: 11:30 AM - 1PM
Place: TVC, 1155 University SE